Compare Stocks: GYRE, MOR, RGC, and ATAI

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Beckley	$7.39 +0.7%	$6.73	$3.27 ▼ $7.45	$2.72B	1.54	6.94 million shs	10.31 million shs
GYRE Gyre Therapeutics	$6.86 +6.5%	$6.50	$5.44 ▼ $9.42	$718.12M	1.92	53,731 shs	56,021 shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A
RGC Regencell Bioscience	$6.89 +6.3%	$5.74	$4.51 ▼ $69.00	$3.20B	1.45	165,736 shs	656,032 shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Beckley	-0.14%	-0.14%	+2.23%	+85.82%	+62.39%
GYRE Gyre Therapeutics	+1.26%	-3.59%	+4.72%	+2.38%	-20.30%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	0.00%
RGC Regencell Bioscience	+2.69%	+17.39%	+7.11%	-67.58%	-53.11%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ATAI Atai Beckley	$7.39 +0.7%	$6.73	$3.27 ▼ $7.45	$2.72B	1.54	6.94 million shs	10.31 million shs
GYRE Gyre Therapeutics	$6.86 +6.5%	$6.50	$5.44 ▼ $9.42	$718.12M	1.92	53,731 shs	56,021 shs
MOR MorphoSys	$18.96	$18.96	$4.18 ▼ $19.50	$2.86B	1.2	1.02 million shs	N/A
RGC Regencell Bioscience	$6.89 +6.3%	$5.74	$4.51 ▼ $69.00	$3.20B	1.45	165,736 shs	656,032 shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ATAI Atai Beckley	-0.14%	-0.14%	+2.23%	+85.82%	+62.39%
GYRE Gyre Therapeutics	+1.26%	-3.59%	+4.72%	+2.38%	-20.30%
MOR MorphoSys	0.00%	0.00%	0.00%	0.00%	0.00%
RGC Regencell Bioscience	+2.69%	+17.39%	+7.11%	-67.58%	-53.11%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ATAI Atai Beckley	2.06	Hold	$10.56	42.85% Upside
GYRE Gyre Therapeutics	1.67	Reduce	$16.00	133.24% Upside
MOR MorphoSys	0.00	N/A	N/A	N/A
RGC Regencell Bioscience	1.00	Sell	N/A	N/A

Current Analyst Ratings Breakdown

Latest GYRE, MOR, RGC, and ATAI Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/18/2026	GYRE Gyre Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell
8/17/2026	ATAI Atai Beckley	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Outperform ➝ Market Perform
8/13/2026	ATAI Atai Beckley	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
8/12/2026	ATAI Atai Beckley	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$12.00 ➝ $8.00
8/12/2026	ATAI Atai Beckley	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$12.00 ➝ $8.00
8/7/2026	GYRE Gyre Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/20/2026	ATAI Atai Beckley	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$7.45
7/20/2026	ATAI Atai Beckley	Berenberg Bank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
7/20/2026	ATAI Atai Beckley	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral	$25.00 ➝ $7.50
7/17/2026	ATAI Atai Beckley	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold
7/17/2026	ATAI Atai Beckley	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Hold

(Data available from 9/4/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ATAI Atai Beckley	$4.09M	670.09	N/A	N/A	$0.69 per share	10.71
GYRE Gyre Therapeutics	$116.59M	6.56	$0.24 per share	28.98	$1.28 per share	5.36
MOR MorphoSys	$238.28M	11.99	N/A	N/A	$0.35 per share	54.17
RGC Regencell Bioscience	N/A	N/A	N/A	N/A	$0.01 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ATAI Atai Beckley	-$660.05M	-$2.18	N/A	N/A	N/A	-14,938.36%	-88.30%	-58.88%	11/12/2026 (Estimated)
GYRE Gyre Therapeutics	$5.03M	-$0.21	N/A	N/A	N/A	-15.47%	-6.57%	-5.35%	11/6/2026 (Estimated)
MOR MorphoSys	-$205.35M	-$3.48	N/A	N/A	N/A	-226.79%	-694.31%	-22.55%	N/A
RGC Regencell Bioscience	-$3.58M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Latest GYRE, MOR, RGC, and ATAI Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
8/11/2026	Q2 2026	ATAI Atai Beckley	-$0.1075	-$0.09	+$0.0175	-$0.09	$0.60 million	$1.70 million
8/7/2026	Q2 2026	GYRE Gyre Therapeutics	-$0.0567	-$0.12	-$0.0633	-$0.12	$26.49 million	$29.11 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ATAI Atai Beckley	N/A	N/A	N/A	N/A	N/A
GYRE Gyre Therapeutics	N/A	N/A	N/A	N/A	N/A
MOR MorphoSys	N/A	N/A	N/A	N/A	N/A
RGC Regencell Bioscience	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ATAI Atai Beckley	N/A	N/A	N/A
GYRE Gyre Therapeutics	N/A	4.26	3.86
MOR MorphoSys	4.98	1.38	1.38
RGC Regencell Bioscience	N/A	1.41	N/A

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ATAI Atai Beckley	28.41%
GYRE Gyre Therapeutics	23.99%
MOR MorphoSys	18.38%
RGC Regencell Bioscience	0.13%

Insider Ownership

Company	Insider Ownership
ATAI Atai Beckley	19.80%
GYRE Gyre Therapeutics	9.50%
MOR MorphoSys	0.05%
RGC Regencell Bioscience	2.00%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ATAI Atai Beckley	80	370.86 million	297.43 million	Optionable
GYRE Gyre Therapeutics	40	111.51 million	100.92 million	No Data
MOR MorphoSys	730	150.62 million	150.55 million	Not Optionable
RGC Regencell Bioscience	10	494.49 million	484.60 million	N/A

GYRE, MOR, RGC, and ATAI Headlines

Recent News About These Companies

Regencell Bioscience (NASDAQ:RGC) Trading Up 6.7% - Time to Buy?

September 2 at 12:39 PM | marketbeat.com

RGC Resources: More Likely To Appeal More To Income-Focused Investors

August 18, 2026 | seekingalpha.com

Regencell Bioscience Posts Higher Losses in First-Half 2026 Results Filed on Form 6-K

July 3, 2026 | theglobeandmail.com

Regencell Bioscience surges on apparent short squeeze

July 1, 2026 | msn.com

Regencell Bioscience Holdings Limited (NASDAQ: RGC) Investors Have Until June 23, 2026 to Seek a Leadership Role in the Securities Class Action Lawsuit Contact Kaplan Fox ...

June 30, 2026 | theglobeandmail.com

Pomerantz Law Firm Announces the Filing of a Class Action Against Regencell Bioscience Holdings Limitedand Certain Officers – RGC

June 23, 2026 | globenewswire.com

Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

June 23, 2026 | prnewswire.com

Regencell Deadline Today: Rosen Law Firm Urges Regencell Bioscience Holdings Limited (NASDAQ: RGC) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

June 23, 2026 | businesswire.com

Portnoy Law Firm Announces Class Action on Behalf of Regencell Bioscience Holdings Limited Investors

June 23, 2026 | globenewswire.com

RGC Shareholder Alert: June 23, 2026 Lead Plaintiff Deadline in Regencell Bioscience Holdings Limited Securities Class Action - Contact The Gross Law Firm

June 23, 2026 | prnewswire.com

RGC FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds Regencell Bioscience (RGC) Investors of Securities Class Action Lawsuit Deadline on June 23, 2026

June 23, 2026 | tmcnet.com

RGC Deadline: RGC Investors with Losses in Excess of $100K Have Opportunity to Lead Regencell Bioscience Holdings Limited Securities Fraud Lawsuit

June 23, 2026 | prnewswire.com

Deadline Soon: Regencell Bioscience Holdings Limited (RGC) Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

June 22, 2026 | tmcnet.com

REGENCELL DEADLINE JUNE 23rd: Bragar Eagel & Squire, P.C. Urgently Reminds Regencell Bioscience Holdings Limited Investors They Have Until June 23rd to Contact the Firm Seeking Lead Plaintiff Role

June 22, 2026 | globenewswire.com

Deadline Soon: Regencell Bioscience Holdings Limited (RGC)Â Shareholders Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

June 22, 2026 | businesswire.com

DEADLINE ALERT for LKQ, RGC, and GLOB: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

June 22, 2026 | globenewswire.com

Levi & Korsinsky Reminds Shareholders of a Lead Plaintiff Deadline of June 23, 2026 in Regencell Bioscience Holdings Limited Lawsuit - RGC

June 22, 2026 | globenewswire.com

REGENCELL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Regencell Bioscience Holdings Limited ...

June 21, 2026 | gazettextra.comG

REGENCELL DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages Regencell Bioscience Holdings Limited Investors with Losses in Excess of $100K to Secure Counsel Before Important June 23 Deadline in Securities Class Action – RGC

June 21, 2026 | globenewswire.com

Bronstein, Gewirtz & Grossman LLC Urges Regencell Bioscience Holdings Ltd. Investors to Act: Class Action Filed Alleging Investor Harm

June 21, 2026 | globenewswire.com

RGC DEADLINE: The Gross Law Firm Reminds Regencell Bioscience Holdings Limited Investors of Upcoming Securities Class Action Deadline

June 19, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

GYRE, MOR, RGC, and ATAI Company Descriptions

Atai Beckley NASDAQ:ATAI

$7.39 +0.05 (+0.68%)

As of 04:00 PM Eastern

Atai Beckley N.V., a clinical-stage biopharmaceutical company, develops and invests in various therapeutics to treat depression, anxiety, addiction, and other mental health disorders. Its product candidates include COMP360, a proprietary psilocybin which is in Phase 3 program; BPL-003, an intranasal formulation that is in Phase 2a and 2b clinical studies; TRD; VLS-01, an transmucosal film in Phase 1b clinical studies; and ELE-101, a serotonergic psychedelic that is in Phase 1/2a study, for the treatment of treatment resistant depression. The company also develop IBX-210, an intravenous formulation of ibogaine, and DMX-1002, an oral formulation of ibogaine indicated for the treatment of opioid use disorder; EMP-01, an oral formulation of an R-MDMA derivative being developed for the treatment of post-traumatic stress disorder; and EGX-A and EGX-B, psychedelic-like with novel, non-tryptamine structures with differentiated 5-HT receptor pharmacology. In addition, it offers RL-007, an orally bioavailable compound, which is a pro-cognitive neuromodulator for cognitive impairment associated with schizophrenia; and GRX-917, a deuterated etifoxine for the treatment of generalize anxiety disorder. Further, the company develops PCN-101, a subcutaneous formulation of R-ketamine, as a therapy for psychiatric indications initially focused on TRD; KUR-101, a formulation of deuterated mitragynine for the treatment of OUD; and RLS-01, indicated for treatment resistant depression. Atai Beckley N.V. was founded in 2018 and is headquartered in Berlin, Germany with offices in New York and London.

Gyre Therapeutics NASDAQ:GYRE

$6.86 +0.42 (+6.52%)

As of 04:00 PM Eastern

Gyre Therapeutics, Inc., a biopharmaceutical company, primarily focuses on the development and commercialization of Hydronidone for the treatment of Metabolic Dysfunction Associated Steatohepatitis in the United States. Its Hydronidone is also being evaluated for the treatment of liver fibrosis across a spectrum of chronic liver diseases. In addition, it advances a product pipeline in China, including Pirfenidone, for dermatomyositis interstitial lung disease, systemic sclerosis-associated interstitial lung disease, and pneumoconiosis, as well as for diabetic kidney disease; and product candidates for acute-on-chronic liver failure, chronic obstructive pulmonary disease, and pulmonary arterial hypertension. The company was founded in 2002 and is headquartered in San Diego, California.

MorphoSys NASDAQ:MOR

$18.96 0.00 (0.00%)

As of 09/3/2026

MorphoSys AG, together with its subsidiaries, engages in the development and commercialization of therapeutics for patients suffering from various cancers in Europe, Asia, and the United States. The company's product pipeline includes Pelabresib that is in Phase 3 trials to treat myelofibrosis and thrombocythemia; Tulmimetostat, a product candidate in Phase 1/2 trials for the treatment of solid tumors and lymphomas; Felzartamab, an antibody directed against CD38 for renal autoimmune diseases and relapsed/refractory multiple myeloma; Ianalumab, a candidate in Phase 3 clinical trials for Sjögren's disease, lupus nephritis, and other autoimmune diseases; Abelacimab that is in Phase 3 trials for venous thromboembolism prevention and cancer-associated thrombosis; Setrusumab, which is in Phase 2/3 trials for osteogenesis imperfecta; and Bimagrumab, a product candidate in Phase 2b trials for adult obesity. It also develops MOR210/TJ210/HIB210 that is in Phase 1 clinical trials for relapsed or refractory advanced solid tumors; and NOV-8, a candidate in Phase 2 trials for the treatment of pulmonary sarcoidosis and dermatitis. The company has collaboration and licensing agreements with I-Mab Biopharma, Novartis, Anthos Therapeutics, Ultragenyx, Mereo BioPharma, Lilly, Human Immunology Biosciences, Inc. Incyte Corporation, and Xencor, Inc. MorphoSys AG was founded in 1992 and is headquartered in Planegg, Germany.

Regencell Bioscience NASDAQ:RGC

$6.89 +0.41 (+6.33%)

As of 04:00 PM Eastern

Regencell Bioscience Holdings Limited operates a Traditional Chinese medicine (TCM) bioscience company. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, primarily attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GYRE, MOR, RGC, and ATAI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GYRE, MOR, RGC, and ATAI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GYRE, MOR, RGC, and ATAI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GYRE, MOR, RGC, and ATAI Company Descriptions

Atai Beckley NASDAQ:ATAI

Gyre Therapeutics NASDAQ:GYRE

MorphoSys NASDAQ:MOR

Regencell Bioscience NASDAQ:RGC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest GYRE, MOR, RGC, and ATAI Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest GYRE, MOR, RGC, and ATAI Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

GYRE, MOR, RGC, and ATAI Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

GYRE, MOR, RGC, and ATAI Company Descriptions

Atai Beckley NASDAQ:ATAI

Gyre Therapeutics NASDAQ:GYRE

MorphoSys NASDAQ:MOR

Regencell Bioscience NASDAQ:RGC

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools